MP 2269

Drug Profile

MP 2269

Latest Information Update: 20 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mallinckrodt Medical
  • Class Gadolinium-containing contrast agents; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 20 Jul 2011 Discontinued - Preclinical for Vascular disorders in USA (IV)
  • 01 Nov 2000 Mallinckrodt has been acquired by Tyco International
  • 26 Jan 2000 Preclinical development for Vascular disorders (diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top